Actuate Therapeutics Inc. has announced plans to advance its elraglusib oral tablet into a Phase 1/2 clinical program targeting refractory cancers, including metastatic melanoma. The program builds on encouraging early clinical evidence of monotherapy activity from a previously completed trial using the IV formulation of elraglusib, which included a complete response lasting over six years in a patient with advanced, refractory BRAFV600E-mutated metastatic melanoma. The upcoming Phase 1 portion, scheduled to begin in the second half of 2026, will assess safety, dosing, and preliminary anti-tumor activity of the oral tablet. The results referenced were from prior studies, and the new research will be conducted and presented in the future.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9629383) on January 21, 2026, and is solely responsible for the information contained therein.